Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis

A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort)

BACKGROUND: Stent thrombosis (ST) is a serious complication following coronary stenting. Intravascular optical coherence tomography (OCT) may provide insights into mechanistic processes leading to ST. We performed a prospective, multicenter study to evaluate OCT findings in patients with ST.

METHODS: Consecutive patients presenting with ST were prospectively enrolled in a registry by using a centralized telephone registration system. After angiographic confirmation of ST, OCT imaging of the culprit vessel was performed with frequency domain OCT. Clinical data were collected according to a standardized protocol. OCT acquisitions were analyzed at a core laboratory. Dominant and contributing findings were adjudicated by an imaging adjudication committee.

RESULTS: Two hundred thirty-one patients presenting with ST underwent OCT imaging; 14 (6.1%) had image quality precluding further analysis. Of the remaining patients, 62 (28.6%) and 155 (71.4%) presented with early and late/very late ST, respectively. The underlying stent type was a new-generation drug-eluting stent in 50.3%. Mean reference vessel diameter was 2.9±0.6 mm and mean reference vessel area was 6.8±2.6 mm². Stent generation drug-eluting stent in 50.3%. Mean reference vessel diameter and late/very late ST, respectively. The underlying stent type was a new-generation drug-eluting stent in 50.3%. Mean reference vessel diameter was 2.9±0.6 mm and mean reference vessel area was 6.8±2.6 mm². Stent underexpansion (stent expansion index <0.8) was observed in 44.4% of patients. The predicted average probability (95% confidence interval) that any frame had uncovered (or thrombus-covered) struts was 99.3% (96.1–99.9), 96.6% (92.4–98.5), 34.3% (15.0–60.7), and 9.6% (6.2–14.5) and malapposed struts was 21.8% (8.4–45.6), 8.5% (4.6–15.3), 6.7% (2.5–16.3), and 2.0% (1.2–3.3) for acute, subacute, late, and very late ST, respectively. The most common dominant finding adjudicated for acute ST was uncovered struts (66.7% of cases); for subacute ST, the most common dominant finding was uncovered struts (61.7%) and underexpansion (25.5%); for late ST, the most common dominant finding was uncovered struts (33.3%) and severe restenosis (19.1%); and for very late ST, the most common dominant finding was neoatherosclerosis (31.3%) and uncovered struts (20.2%). In patients presenting very late ST, uncovered stent struts were a common dominant finding in drug-eluting stents, and neoatherosclerosis was a common dominant finding in bare metal stents.

CONCLUSIONS: In patients with ST, uncovered and malapposed struts were frequently observed with the incidence of both decreasing with longer time intervals between stent implantation and presentation. The most frequent dominant observation varied according to time intervals from index stenting: uncovered struts and underexpansion in acute/subacute ST and neoatherosclerosis and uncovered struts in late/very late ST.

© 2017 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
**Clinical Perspective**

**What Is New?**
- This report represents the largest available series of patients with optical coherence tomography imaging during stent thrombosis presentation and includes findings from patients treated predominantly with current-generation drug-eluting stents.
- The dominant findings at optical coherence tomography vary according to the time interval between index stenting and presentation with stent thrombosis.
- Uncovered struts and stent underexpansion were the most common observations in acute/subacute stent thrombosis and neoatherosclerosis and uncovered struts were the most common findings in late/very late stent thrombosis.

**What Are the Clinical Implications?**
- Improved acute deployment techniques with post-stent dilatation where appropriate may significantly impact stent thrombosis by reducing underexpansion and malapposition.
- The impact of dedicated clinical strategies for the prevention and treatment of neoatherosclerosis should be investigated in future clinical studies.

Percutaneous coronary intervention with stent implantation is a successful treatment for patients with obstructive coronary artery disease and has been shown to improve symptoms, and to reduce mortality in certain settings, as well.\(^1,2\) The most serious complication of coronary stenting is abrupt thrombotic occlusion, which often results in Q-wave myocardial infarction and significantly impacts life expectancy.\(^3,4,5\) Although the absolute risk of stent thrombosis is low after treatment with current-generation drug-eluting stents (DES),\(^6\) the large number of patients implanted with coronary stents worldwide makes this condition a significant health issue.

Numerous risk factors for stent thrombosis have been identified from case-control studies.\(^7\) These factors are related to specific patient characteristics and the types of disease patterns treated. In addition, risk characteristics attributed to the type of implanted device have been well defined.\(^7\) Specifically, higher risk was observed with first-generation DES in comparison with bare metal stents, although new-generation DES seem to be associated with a comparable or lower risk of stent thrombosis in comparison with uncoated stents.\(^8,9,10\)

Detailed understanding of the underlying conditions in the stented segment at the time of the stent thrombosis event remains an important clinical need. In particular, although imaging with intravascular ultrasound can help define stent-vessel interactions, this modality is limited by modest axial resolution.\(^11\) Recently, intravascular optical coherence tomography (OCT) has become widely available in clinical practice. This technology permits rapid evaluation of stent coverage and apposition, and detailed characterization of neo-intimal tissue and vessel wall pathology.\(^12\) In the setting of the PRESTIGE registry (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European) effort, we collected information on patients presenting with stent thrombosis undergoing intracoronary imaging with OCT at a network of centers across Europe. In the present report, we present the key findings from our analysis.

**METHODS**

**Study Population and Patient Treatment**

Consecutive patients presenting with definite stent thrombosis, undergoing percutaneous coronary intervention at 29 participating centers with OCT imaging capability, were prospectively enrolled in the multicenter PRESTIGE registry using a centralized telephone registration system. A list of participating centers is provided in the Appendix in the online-only Data Supplement.\(^13\) Definite stent thrombosis was defined according to Academic Research Consortium criteria.\(^14\) Clinical, procedural, and imaging data were collected according to a standardized protocol and entered by site investigators in a central electronic database (Open Clinica, Leuven Coordinating Center, Leuven, Belgium) checked by centralized monitoring queries. Platelet reactivity was measured according to the available assays per center using the VerifyNow P2Y\(_{12}\) (Accriva Diagnostics) or Multiplate ADP assay (Roche Diagnostics International Ltd) according to manufacturer’s instructions. High platelet reactivity was defined as HPR-ADP >208 P2Y\(_{12}\) Units by the VerifyNow P2Y\(_{12}\), and as >46 U (U: 1 U=10 AUxmin) by the Multiplate ADP assay. Type of underlying stent was classified as a bare metal stent, early-generation DES (durable polymer sirolimus-eluting stents [Cypher, Cordis]), durable polymer paclitaxel-eluting stents [Taxus, Boston Scientific], or durable polymer zotarolimus-eluting stents [Endeavor, Medtronic Inc]), newer-generation DES (all other metallic-backbone DES), or bioresorbable DES.\(^9\) The study complied with the Declaration of Helsinki. The ethical review committee at each participating institution approved the study, and all patients provided written informed consent. The study was funded by the European Union under the Seventh Framework Program FP7/2007 to 2013, grant agreement HEALTH-F2-2010 to 260309 (PRESTIGE).
Study Procedures
Patients enrolled in the PRESTIGE registry underwent percutaneous coronary intervention according to local practices. After angiographic confirmation of stent thrombosis, a guidewire was advanced distally in the culprit vessel across the site of occlusion. The use of OCT before and after percutaneous coronary intervention procedures was recommended in all patients. Use of thrombectomy with manual aspiration was encouraged to restore effective flow and to reduce residual thrombus before OCT image acquisition. In selected cases, small balloon dilation (≤2.0 mm in diameter) at low pressure was permitted if image quality remained insufficient after thrombectomy. OCT image acquisition was discouraged in patients presenting in a medical condition precluding safe OCT acquisition (eg, unstable electric or hemodynamic conditions or reported chronic renal insufficiency). During the procedure, patients were treated with intravenous heparin or bivalirudin. Use of glycoprotein inhibitors was at the discretion of the treating physician.

OCT Data Acquisition
Following administration of intracoronary nitrates, OCT was performed with a nonocclusive imaging technique using commercially available frequency domain OCT imaging systems (C7XR, Ilumien or Ilumien Optis, St. Jude Medical). In brief, after restoration of flow, a rapid exchange imaging catheter (Dragonfly or Dragonfly Duo, St. Jude Medical) was advanced beyond the stented segment. An OCT pullback of the entire stented segment, including distal and proximal reference sites, was performed with contrast injection through the guiding catheter at 3 to 5 mL/s. If the stented segment was too long to be imaged in a single pullback, an additional pullback was acquired using angiographic landmarks for appropriate imaging catheter position and view.

OCT Quantitative Analysis
Raw data of OCT image acquisitions were collected and sent to a centralized core laboratory (ISAResearch Center) for off-line analyses. Each OCT sequence was assessed and measured by independent readers experienced in OCT imaging analysis, blinded to patient characteristics and timing of stent thrombosis (see the Appendix and Figure I in the online-only Data Supplement). Initially, a quality screening of the entire sequence was performed to confirm sufficient quality of imaging to permit the analysis. Reasons for exclusion were insufficient image quality because of the poor clearance of blood, missed region of interest with incomplete stent visualization, excessive remaining thrombus obscuring the stent assessment, or the presence of imaging artifacts precluding the analysis. Nonanalyzable frames were defined as frames with <45° of visible lumen border (eg, attributable to the presence of thrombus or side branch). Stent struts located across the ostium of side branches were excluded from the analysis of coverage and apposition. Quantitative and morphometric analyses were performed every 1 mm along the entire target segment. Dedicated software (St. Jude Medical) was used for quantification. Further details and definitions are provided in the Appendix in the online-only Data Supplement.

Imaging Adjudication Committee OCT Analysis
An imaging adjudication committee adjudicated the findings at the time of stent thrombosis based on systematic review of all acquired OCT pullbacks in dedicated sessions at the central core laboratory. The committee reviewed each pullback in detail, scoring for the presence or absence of findings according to a prespecified protocol. OCT images were analyzed without the knowledge of patient/stent characteristics or timing of stent thrombosis. The composition of the committee is listed in the Appendix in the online-only Data Supplement. Each OCT pullback was assessed in both longitudinal and cross-sectional views for the presence of a single dominant finding at stent thrombosis (Figure I in the online-only Data Supplement). If no single dominant finding was assessed, this was recorded. Additional findings assessed to be of lesser relevance were adjudicated as contributory. In case of disagreement, a decision was made by consensus. The following categories were considered for visual adjudication: stent underexpansion (defined as minimum stent area <80% of the mean of proximal and distal vessel reference area), edge dissection (proximal or distal to the stented segment, involving the intima and media with a circumferential extent at least of one-third of the vessel contour and a longitudinal extent >3 mm), overlapping stents, stent fracture, uncovered stent struts, malapposed stent struts, presence of interstrut cavities, in-stent restenosis, and neoatherosclerosis (in the presence of plaque rupture or in association with thin cap fibroatheroma adjacent to the site of maximum thrombus burden). Restenosis was defined as the presence of >50% diameter stenosis in the stented segment. In the presence of both in-stent restenosis and neoatherosclerosis, neoatherosclerosis was considered as the dominant finding if either of the 2 associated factors listed above were present. If none of these characteristics was present, the label no contributing factor identifiable was recorded.

Statistical Analysis
Continuous data are presented as mean (SD) or median (25th–75th percentiles). Categorical data are presented as observed frequencies and proportions (%). Patients were analyzed according to the time interval between index stenting and stent thrombosis presentation, classified as acute (<24 hours), subacute (24 hours to 30 days), late (>30 days to 1 year), and very late (>1 year). Differences between groups were assessed for statistical significance using a Wilcoxon rank sum test or a Kruskal-Wallis test for continuous data and χ² test (or Fisher exact test where the expected cell value was <5) for categorical variables. Repeatability data were analyzed by calculating the within-patient SD and repeatability coefficient, and the intraclass correlation coefficient, described by Shrout and Fleiss for the case when all patients are rated by the same raters who are assumed to be a random subset of all possible raters.
RESULTS

A total of 675 patients with ST were enrolled in the PRESTIGE ST registry at participating centers. Of these patients, 231 underwent OCT imaging at the time of presentation (Figure II in the online-only Data Supplement). Fourteen patients had image quality precluding further analysis (poor quality attributable to blood contamination [n=6], or excessive remaining thrombus [n=8]). The remaining 217 patients comprised the primary study cohort for the current analysis.

Baseline clinical characteristics of patients according to presentation with acute/subacute (≤30 days) or late/very late (>30 days) ST are shown in Table 1. Overall, 62 (28.6%) patients presented with acute/subacute and 155 (71.4%) presented with late/very late ST. Median time from index stenting to presentation with acute/subacute (<30 days) was 4 (2–8) days and 1804 (692–2953) days, respectively. Patients with acute/subacute ST in comparison with late/very late were older, more likely to have diabetes mellitus, more likely to be on dual antiplatelet therapy, and less likely to have had a prior myocardial infarction. Regarding clinical presentation, 158 patients (73.8%) presented with ST-segment–elevation myocardial infarction, 46 (21.5%) with non-ST-segment–elevation myocardial infarction, and 10 (4.7%) with unstable angina.

Blood sampling for platelet function testing was available in 81 of 217 (37.3%) of the patients. Data from Verify Now P2Y12 assay was available in 49 patients and Multiplate ADP assay in 51 patients. The results are shown in Table I in the online-only Data Supplement. Overall, 37 of 49 (75.5%) and 34 of 51 (66.7%) patients had high platelet reactivity. There was no difference in the proportion of patients with high platelet reactivity between early and late ST groups with either assay (P=0.18 and 0.31, respectively).

Table 1. Patient Clinical Characteristics at Time of Presentation With Stent Thrombosis

<table>
<thead>
<tr>
<th></th>
<th>Early Stent Thrombosis (n=62)</th>
<th>Late/Very Late Stent Thrombosis (n=155)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>66.4±11.2</td>
<td>62.6±12.0</td>
<td>0.04</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>26.9±4.4</td>
<td>27.2±4.4</td>
<td>0.62</td>
</tr>
<tr>
<td>Male</td>
<td>48/62 (77.4)</td>
<td>130/155 (83.9)</td>
<td>0.26</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>24/62 (38.7)</td>
<td>30/155 (19.4)</td>
<td>0.003</td>
</tr>
<tr>
<td>Insulin dependent</td>
<td>8/62 (12.9)</td>
<td>5/152 (3.3)</td>
<td>0.008</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>53/57 (93.0)</td>
<td>128/136 (94.1)</td>
<td>0.77</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>33/62 (53.2)</td>
<td>66/149 (44.3)</td>
<td>0.24</td>
</tr>
<tr>
<td>Active smoker</td>
<td>16/59 (27.1)</td>
<td>46/151 (30.5)</td>
<td>0.63</td>
</tr>
<tr>
<td>Severely impaired left ventricular function*</td>
<td>2/62 (3.2)</td>
<td>7/155 (4.5)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Prior bypass operation</td>
<td>4/62 (6.5)</td>
<td>10/155 (6.5)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Prior myocardal infarction</td>
<td>19/62 (30.6)</td>
<td>81/155 (52.3)</td>
<td>0.004</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>1/62 (1.6)</td>
<td>8/155 (5.2)</td>
<td>0.45</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td></td>
<td></td>
<td>0.47</td>
</tr>
<tr>
<td>ST-segment–elevation myocardial infarction</td>
<td>49/62 (79.0)</td>
<td>109/152 (71.7)</td>
<td></td>
</tr>
<tr>
<td>Non-ST-segment–elevation myocardial infarction</td>
<td>10/62 (16.1)</td>
<td>36/152 (23.7)</td>
<td></td>
</tr>
<tr>
<td>Unstable angina</td>
<td>3/62 (4.8)</td>
<td>7/152 (4.6)</td>
<td></td>
</tr>
<tr>
<td>Antiplatelet therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual antiplatelet therapy</td>
<td>46/62 (74.2)</td>
<td>34/154 (21.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aspirin</td>
<td>53/62 (85.5)</td>
<td>126/154 (81.3)</td>
<td>0.66</td>
</tr>
<tr>
<td>P2Y12, inhibitor</td>
<td>52/62 (83.9)</td>
<td>47/154 (26.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Oral anticoagulation</td>
<td>5/59 (8.5)</td>
<td>13/142 (9.2)</td>
<td>0.88</td>
</tr>
<tr>
<td>Creatine kinase maximum (U/L)</td>
<td>1020 (245–2703)</td>
<td>523 (248–1429)</td>
<td>0.33</td>
</tr>
<tr>
<td>Creatine kinase MB maximum (µg/L)</td>
<td>142 (42–248)</td>
<td>71 (26–154)</td>
<td>0.04</td>
</tr>
<tr>
<td>Troponin T maximum (µg/L)</td>
<td>6 (1–40)</td>
<td>5 (1–28)</td>
<td>0.60</td>
</tr>
</tbody>
</table>

Data are shown as n (%) or mean±SD; percentages were calculated on the basis of patients with available information. For creatine kinase maximum, creatine kinase MB maximum, and Troponin T maximum, median and interquartile range (Q1–Q3) are given.

*Severely impaired left ventricular function was defined as ejection fraction <30%.

In terms of the index stenting procedure, there were no significant differences between the groups regarding presentation (P=0.064): overall 85 of 209 patients (40.6%) presented with ST-segment–elevation myocardial infarction, 79 of 209 (37.8%) patients presented with acute coronary syndrome, and 45 of 209 (21.5%) patients presented with stable coronary disease. Ten of 204 (4.9%) patients underwent intra-
vascular imaging guidance at the time of index intervention.

Lesion and procedural characteristics of patients according to presentation are reported in Table 2. The left anterior descending artery was the most commonly involved culprit vessel. A total of 333 stents were implanted in target vessels presenting ST: 110 (33.0%) bare metal stents, 45 (13.9%) first-generation DES, 163 (50.3%) newer-generation DES, 3 DES of unknown type, and 6 (1.8%) bioresorbable stents; in 6 patients (1.8%), the stent type could not be determined.

There were no significant differences between patients with ST with analyzable OCT imaging who were included in the present analysis (n=217) versus those without (n=458) in terms of proportion of patients with acute/subacute and late/very late ST (see the Appendix in the online-only Data Supplement). In comparison with patients with OCT imaging, there was a higher proportion of patients with prior myocardial infarction, ST in a saphenous vein graft, and unknown stent type at baseline in patients without OCT imaging. Otherwise there were no significant differences between the groups (Table II in the online-only Data Supplement).

### OCT Core Laboratory Analysis

OCT morphometric data in patients with acute, subacute, late, and very late ST are reported in Table 3. Overall mean reference vessel diameter was 2.9±0.6 mm and mean reference vessel area was 6.8±2.6 mm². Mean minimum stent diameter was 2.6±0.6 mm and mean minimum stent area was 5.8±2.5 mm². A stent expansion index <0.8 was observed in 44.4% of all patients (Figure 1). In the subgroup of patients with subacute ST, mean expansion index was 0.7±0.2, and a stent expansion index <0.8 was observed in 65.8% of these patients.

OCT analysis of stent-vessel interaction for each lesion according to the time of presentation is reported in Table 4. A total of 5704 frames were quantitatively analyzed with a mean number of 26.5±13.2 frames per patient; 96.7% of target regions showed at least 1 frame with any remaining thrombus.

The number of ST lesions with any frame of the pullback showing uncovered struts significantly decreased according to the time of presentation: 100%, 89.1%, 76.2%, and 54.1% for acute, subacute, late, and very late ST, respectively (P<0.001) (Figure 1). In patients presenting with acute or subacute ST, a median of 100% of frames were uncovered or covered with thrombus, in comparison with 50.0% and 11.4% in patients with late or very late ST (P<0.001). The maximum longitudinal extent of thrombus and uncovered struts was greatest

---

**Table 2. Angiographic and Procedural Characteristics of Patients With Stent Thrombosis**

<table>
<thead>
<tr>
<th>Culprit vessel*</th>
<th>Early Stent Thrombosis (n=62)</th>
<th>Late/Very Late Stent Thrombosis (n=155)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left main only</td>
<td>0/62 (0)</td>
<td>2/152 (1.3)</td>
<td>0.98</td>
</tr>
<tr>
<td>Left anterior descending artery only</td>
<td>32/62 (51.6)</td>
<td>58/152 (38.2)</td>
<td>0.06</td>
</tr>
<tr>
<td>Left circumflex artery only</td>
<td>6/62 (9.7)</td>
<td>23/152 (15.1)</td>
<td>0.31</td>
</tr>
<tr>
<td>Right coronary artery only</td>
<td>19/62 (30.7)</td>
<td>59/152 (38.8)</td>
<td>0.30</td>
</tr>
<tr>
<td>Left anterior descending artery and left circumflex artery</td>
<td>3/62 (4.8)</td>
<td>3/152 (2.0)</td>
<td>0.46</td>
</tr>
<tr>
<td>Left anterior descending artery and right coronary artery</td>
<td>1/62 (1.6)</td>
<td>1/152 (0.7)</td>
<td>0.98</td>
</tr>
<tr>
<td>Left circumflex artery and right coronary artery</td>
<td>0/62 (0)</td>
<td>3/152 (2.0)</td>
<td>0.73</td>
</tr>
<tr>
<td>Saphenous vein graft</td>
<td>1/62 (1.6)</td>
<td>3/152 (2.0)</td>
<td>0.74</td>
</tr>
<tr>
<td>Bifurcation lesion</td>
<td>14/62 (22.6)</td>
<td>24/143 (16.8)</td>
<td>0.33</td>
</tr>
</tbody>
</table>

| Number of stents implanted in vessel with stent thrombosis; Stent type at index procedure | 104 | 229 |
| Bare metal stent | 29/104 (27.9) | 81/229 (35.4) | 0.17    |
| Early-generation DES | 1/104 (1.0) | 44/229 (19.2) | <0.001  |
| Newer-generation DES | 68/104 (65.4) | 95/229 (41.5) | <0.001  |
| Bioreabsorbable DES | 6/104 (5.8) | 0/229 (0) | 0.0017  |
| DES, unknown type† | 0/104 (0) | 3/229 (1.3) | 0.65    |
| Unknown | 0/104 (0) | 6/229 (2.6) | 0.21    |
| Stent diameter, mm | 3.1±0.5 | 3.2±2.0 | 0.38    |
| Stent length, mm | 20.3±6.0 | 19.3±6.4 | 0.23    |
| TIMI flow at presentation | 4/104 (3.5%) | 20/229 (8.8%) | 0.11 |
| 0/1 | 51/61 (83.6) | 117/151 (77.5) |
| 2 | 2/61 (3.3) | 19/151 (12.6) |
| 3 | 8/61 (13.1) | 15/151 (9.9) |
| Thrombus aspiration, n (%) | 55/61 (90.2) | 136/151 (88.3) | 0.70    |
| Balloon angioplasty, n (%) | 51/60 (85) | 135/153 (88.2) | 0.52    |

Data are shown as n (%) or mean±SD. DES indicates drug-eluting stent; and TIMI, thrombolysis in myocardial infarction.

*Eleven patients had 2-vessel stent thrombosis; in 3 patients, the culprit vessel location was not entered.
†Three patients had a metallic-backbone DES stent, but because of the lack of information, the stent could not be classified as either first or second generation.
in patients with acute and subacute ST and decreased over time. The number of lesions with any frame showing malapposed struts significantly decreased according to the time of presentation: 86.7%, 76.1%, 61.9%, and 37.6% for acute, subacute, late, and very late ST, respectively (P < 0.001). A median of 25% of frames showed malapposition in patients with acute ST in comparison with 10.6%, 4.3%, and 0.0% in patients with subacute, late, and very late ST, respectively (P < 0.001) (Figure 1).

The predicted average probability (95% confidence interval) for any frame to have uncovered (or thrombus-covered) struts was 99.3% (96.1–99.9), 96.6% (92.4–98.5), 34.3% (15.0–60.7), and 9.6% (6.2–14.5), and malapposed struts was 21.8% (8.4–45.6), 8.5% (4.6–15.3), 6.7% (2.5–16.3), and 2.0% (1.2–3.3) for acute, subacute, late, and very late ST, respectively (Table III in the online-only Data Supplement).

The number of lesions showing any frames with core-laboratory–adjudicated neoatherosclerosis or interstrut cavity significantly increased over time. In patients with acute, subacute, or late ST, neoatherosclerosis was not observed. Of lesions in patients presenting with very late ST, 43.6% had at least 1 frame with neoatherosclerosis. In these patients, the mean number of frames with neoatherosclerosis was 3.8.

The predicted average probability (95% confidence interval) for any frame to have struts covered with neoatherosclerosis or interstrut cavities was 0.0% (0.0–0.0), 0.0% (0.0–0.0), 0.0% (0.0–0.0), and 2.8% (1.3–5.9) and 0.0% (0.0–0.0), 0.1% (0.0–0.3), 1.2% (0.3–4.5), and 0.7% (0.3–1.4) for acute, subacute, late, and very late ST, respectively (Table III in the online-only Data Supplement).

### Imaging Adjudication Committee Analysis of Findings

Representative images of dominant findings for acute and subacute ST and late and very late ST are shown in Figure 2 and Figure 3, respectively. The results of the imaging adjudication committee analysis for dominant findings for acute and subacute ST and late and very late ST are shown in Figure 4; the results for contributory findings are shown in Table IV in the online-only Data Supplement. The most commonly adjudicated dominant finding according to presentation was: acute, persistence of uncovered struts (66.7%); subacute, persistence of uncovered struts (61.7%) and underexpansion (25.5%); late, uncovered struts (33.3%) and severe restenosis (19.1%); and very late, neoatherosclerosis (31.3%) and uncovered struts (20.2%).

In patients presenting with very late ST, an analysis of the imaging adjudication findings according to stent type is shown in Figure 5. A variety of causes was seen at each time interval analyzed. Uncovered stent struts comprised a higher proportion of dominant findings in patients treated with DES. In patients with time interval >5 years from stenting, most had been treated with bare metal stents, and the most frequent dominant finding in these patients was neoatherosclerosis (30/45 [66.7%]). Neoatherosclerosis was a frequent finding in patients presenting with very late ST (>1 year, 59/134 patients). Although a higher proportion of patients with neoatherosclerosis had severe stenosis (23/59 [39.0%]) in com-

| Table 3. Optical Coherence Tomography Morphometric Analysis in Patients Presenting With Stent Thrombosis Classified According to Time |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Lesion-Level Analysis | Overall (N=215) | Acute Stent Thrombosis (n=15) | Subacute Stent Thrombosis (n=46) | Late Stent Thrombosis (n=21) | Very Late Stent Thrombosis (n=133) |
| Proximal lumen area, mm² | 7.9±3.4 | 10.1±3.9 | 7.2±3.2 | 7.7±3.9 | 7.9±3.2 |
| Proximal lumen diameter, mm | 3.1±0.7 | 3.5±0.7 | 3.0±0.6 | 3.0±0.8 | 3.1±0.7 |
| Distal lumen area, mm² | 5.6±2.8 | 6.9±4.0 | 4.9±2.4 | 6.4±3.2 | 5.6±2.7 |
| Distal lumen diameter, mm | 2.6±0.6 | 2.9±0.8 | 2.4±0.6 | 2.8±0.7 | 2.6±0.6 |
| Reference area, mm² | 6.8±2.6 | 8.6±3.1 | 6.2±2.4 | 7.3±3.3 | 6.7±2.5 |
| Reference diameter, mm | 2.9±0.6 | 3.2±0.6 | 2.7±0.5 | 3.0±0.7 | 2.9±0.5 |
| Minimum stent area, mm² | 5.8±2.5 | 6.7±2.3 | 4.5±2.0 | 6.1±2.9 | 6.2±2.4 |
| Minimum stent diameter, mm | 2.6±0.6 | 2.9±0.5 | 2.3±0.5 | 2.7±0.7 | 2.7±0.5 |
| Mean stent area, mm² | 7.3±2.7 | 7.9±2.4 | 6.1±2.2 | 8.1±3.9 | 7.5±2.5 |
| Mean stent diameter, mm | 3.0±0.5 | 3.2±0.5 | 2.7±0.5 | 3.1±0.7 | 3.0±0.5 |
| Expansion index | 0.9±0.3 | 0.8±0.3 | 0.7±0.2 | 1.0±0.3 | 1.0±0.3 |
| Stent expansion <80% | 79/178 (44.4%) | 7/14 (50%) | 25/58 (43.1%) | 3/16 (18.8%) | 42/110 (38.2%) |

Data are shown as n (%) or mean±SD.
DISCUSSION

Treatment with current generation stents is generally safe and highly efficacious in preventing restenosis. However, abrupt stent failure attributable to thrombotic stent occlusion continues to occur at a low rate and this typically results in myocardial infarction, not inconsiderable mortality, and a higher rate of subsequent adverse events in comparison with patients presenting with de novo myocardial infarction. A better understanding of the underlying pathophysiological process leading to ST is an important clinical need. In this respect, the increasing availability of high-resolution intravascular imaging with OCT affords new opportunities for clinical evaluation at the time of presentation.

The aim of the present study was to evaluate and summarize OCT imaging findings in patients presenting with ST at a network of centers across Europe. In a population presenting with both early and late/very late ST containing a high proportion of current generation DES and undergoing imaging in the acute setting using current-generation OCT systems the key findings were: (1) detailed analysis of OCT images acquired in the setting of ST was feasible in the selected patients included in this registry; (2) the rate of stent underexpansion was high across all groups and highest in patients with subacute ST; (3) both uncovered struts and malapposed struts were frequently found in patients with ST; both decreased over time, although more than half of lesions with very late ST had frames with uncovered struts and more than a third had malapposed struts; and (4) neoatherosclerosis was a relatively frequent finding in patients with very late ST.

When categorizing patients according to the timing of ST, some clear messages emerge. In patients presenting with acute/subacute ST, uncovered and malapposed stent struts along with underexpansion of the stented coronary segment were identified as key morphological features of ST by OCT. Although it is not unexpected that uncovered stent struts were frequently observed early after stent implantation, this emphasizes the inherent thrombogenicity of stents in this phase, when neointimal healing and reendothelialization are incomplete. Similarly, although the relevance of stent malapposition in isolation is somewhat unclear, the finding of high rates of malapposition in our report is in line with other reports. Indeed, the relevance of flow disturbance, especially occurrence of nonstreamlined flow along malapposed stent struts has recently been shown to be of relevance with regard to acute thrombogenicity of stents. Nevertheless, it may well be that during this time mechanisms other than those detectable by OCT predominate. These include inadequate response to antplatelet therapy, genetic predisposition to hypercoagulability, and patient comorbidities such as diabetes mellitus, reduced left ventricular function, and renal failure. It is interesting to note that residual dissection proximal or distal to the stent edge was relatively infrequently observed in our study in comparison with some other reports, despite systematic analysis of stent edge segments in our analysis protocol.

The high prevalence of stent underexpansion is a noteworthy observation and is in keeping with the known association between acute procedural results and ST. Moreover, residual stenosis within the stented...
segment or small minimal stent area is a well-recog-
nized independent predictor of ST. A stent expan-
sion index <0.8 was observed in >40% of patients, and
approximately two-thirds of patients with subacute ST
had stent expansion indices <0.8. Indeed, the observed
rate in our study is in line with that observed in a recent
case-control study, which found a >2-fold higher rate
of stent underexpansion in patients with ST in com-
parison with patients undergoing routine surveillance
without clinical events (ST group 42.8% versus control
group 16.7%, P=0.05). Moreover, stent underexpansion
was adjudicated as the dominant cause of ST in
25% of these patients. It is noteworthy that the rate
of intravascular imaging guidance at the time of the
original intervention was low (4.9%). These findings
suggest that improved recognition and correction of

| Table 4. Optical Coherence Tomography Analysis of Stent-Vessel Interaction in Patients Presenting With Stent
<p>| Thrombosis Classified According to Time |
|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|</p>
<table>
<thead>
<tr>
<th>Overall (N=215)</th>
<th>Acute Stent Thrombosis (n=15)</th>
<th>Subacute Stent Thrombosis (n=47)</th>
<th>Late Stent Thrombosis (n=21)</th>
<th>Very Late Stent Thrombosis (n=134)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion-level analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of frames analyzed per lesion</td>
<td>26.5±13.2</td>
<td>24.9±12.9</td>
<td>29.0±13.3</td>
<td>29.8±13.0</td>
<td>25.4±13.2</td>
</tr>
<tr>
<td>Any frames with thrombus</td>
<td>208/215 (96.7)</td>
<td>15/15 (100)</td>
<td>46/46 (100)</td>
<td>21/21 (100)</td>
<td>126/133 (94.7)</td>
</tr>
<tr>
<td>Any frames with malapposed struts</td>
<td>111/215 (51.6)</td>
<td>13/15 (86.7)</td>
<td>35/46 (76.1)</td>
<td>13/21 (61.9)</td>
<td>50/133 (37.6)</td>
</tr>
<tr>
<td>Any frames with uncovered struts</td>
<td>144/215 (67.0)</td>
<td>15/15 (100)</td>
<td>41/46 (89.1)</td>
<td>16/21 (76.2)</td>
<td>72/133 (54.1)</td>
</tr>
<tr>
<td>Any frames with interstrut cavities</td>
<td>45/215 (20.9)</td>
<td>0/15 (0)</td>
<td>3/46 (6.5)</td>
<td>7/21 (33.3)</td>
<td>35/133 (26.3)</td>
</tr>
<tr>
<td>Any frames with neoatherosclerosis</td>
<td>58/215 (27.0)</td>
<td>0/15 (0)</td>
<td>0/46 (0)</td>
<td>0/21 (0)</td>
<td>58/133 (43.6)</td>
</tr>
<tr>
<td>Frame-level analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coverage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frames with uncovered struts, n</td>
<td>6.6±8.5</td>
<td>15.7±7.1</td>
<td>13.3±9.5</td>
<td>9.8±11.3</td>
<td>2.8±4.5</td>
</tr>
<tr>
<td>Percentage of frames with uncovered struts, %</td>
<td>14.3 (0–52.4)</td>
<td>65 (52.9–92.0)</td>
<td>55.8 (31.8–80.6)</td>
<td>21.7 (5.6–56.8)</td>
<td>4.2 (0–16.1)</td>
</tr>
<tr>
<td>Maximum length of consecutive uncovered struts, mm</td>
<td>5.3±7.2</td>
<td>14.3±6.3</td>
<td>11.9±8.9</td>
<td>5.7±5.9</td>
<td>2.0±3.4</td>
</tr>
<tr>
<td>Frames with struts covered by thrombus, n</td>
<td>3.3±4.7</td>
<td>5.3±4.8</td>
<td>7.2±6.3</td>
<td>2.4±3.3</td>
<td>1.9±3.2</td>
</tr>
<tr>
<td>Frames with struts covered by thrombus, %</td>
<td>6.5 (0–25.0)</td>
<td>18.8 (8.0–41.7)</td>
<td>28.0 (12.2–50.0)</td>
<td>0 (0–23.5)</td>
<td>0 (0–12.5)</td>
</tr>
<tr>
<td>Maximum length of frames containing thrombus, mm</td>
<td>12.1±10.4</td>
<td>16.7±7.7</td>
<td>19.7±13.4</td>
<td>9.6±6.6</td>
<td>9.3±6.4</td>
</tr>
<tr>
<td>Frames with uncovered struts or struts covered by thrombus, n</td>
<td>9.9±11.0</td>
<td>21.0±6.8</td>
<td>20.5±11.1</td>
<td>12.2±12.1</td>
<td>4.7±6.7</td>
</tr>
<tr>
<td>Frames with uncovered struts or struts covered by thrombus, %</td>
<td>33.3 (2.6–87.5)</td>
<td>100 (95.8–100)</td>
<td>100 (86.4–100)</td>
<td>50.0 (21.7–70.5)</td>
<td>11.4 (0–35.3)</td>
</tr>
<tr>
<td>Apposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frames with malapposed struts, n</td>
<td>2.6±4.3</td>
<td>6.0±6.2</td>
<td>3.3±4.5</td>
<td>4.6±6.1</td>
<td>1.7±3.2</td>
</tr>
<tr>
<td>Frames with malapposed struts, %</td>
<td>2.4 (0–20.0)</td>
<td>25.0 (7.7–45.5)</td>
<td>10.6 (1.8–26.7)</td>
<td>4.3 (0–27.3)</td>
<td>0.0 (0–9.3)</td>
</tr>
<tr>
<td>Maximum length of consecutive malapposed struts, mm</td>
<td>1.8±2.9</td>
<td>4.1±5.5</td>
<td>2.1±2.4</td>
<td>2.8±3.8</td>
<td>1.2±2.3</td>
</tr>
<tr>
<td>Malapposition area, mm²</td>
<td>0.2±0.6</td>
<td>0.5±0.9</td>
<td>0.2±0.4</td>
<td>0.5±1.3</td>
<td>0.2±0.4</td>
</tr>
<tr>
<td>Maximum malapposition area, mm²</td>
<td>1.1±2.3</td>
<td>1.9±3.3</td>
<td>0.7±1.0</td>
<td>1.8±3.0</td>
<td>1.0±2.3</td>
</tr>
<tr>
<td>Maximum malapposition distance, mm</td>
<td>0.1±0.2</td>
<td>0.1±0.2</td>
<td>0.1±0.1</td>
<td>0.1±0.2</td>
<td>0.1±0.2</td>
</tr>
<tr>
<td>Neoatherosclerosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frames with neoatherosclerosis, n</td>
<td>2.3±4.9</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>3.8±5.8</td>
</tr>
<tr>
<td>Frames with neoatherosclerosis, %</td>
<td>0 (0–8.10)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–30.5)</td>
</tr>
<tr>
<td>Intestrut cavities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frames with interstrut cavities, n</td>
<td>0.8±2.6</td>
<td>0.0±0.0</td>
<td>0.1±0.6</td>
<td>2.1±4.4</td>
<td>1.0±2.6</td>
</tr>
<tr>
<td>Frames with interstrut cavities, %</td>
<td>0 (0–0)</td>
<td>0.0 (0–0)</td>
<td>0.0 (0–0)</td>
<td>0.0 (0–6.1)</td>
<td>0.0 (0–2.9)</td>
</tr>
<tr>
<td>Maximum interstrut cavities depth, mm</td>
<td>0.1±0.2</td>
<td>0.1±0.2</td>
<td>0.0±0.1</td>
<td>0.2±0.3</td>
<td>0.1±0.3</td>
</tr>
</tbody>
</table>

Data are shown as mean±SD or median (interquartile range).
suboptimal stent deployment (eg, stent underexpansion, marked malapposition), perhaps with more liberal use of intravascular imaging-guided stenting, is likely to impact significantly rates of ST.

In patients presenting with late/very late ST, a more heterogeneous profile was observed, with uncovered/malapposed stent struts, underexpansion, and severe restenosis predominant features within the first year and in-stent neoatherosclerosis beyond 1 year. Indeed, although both uncovered and malapposed struts decreased over time, more than half of lesions with very late ST had frames with uncovered struts and more than one-third had malapposed struts. This is in keeping with a prior report by Guagliumi et al\textsuperscript{26} showing higher rates of both uncovered and malapposed struts in patients with ST in comparison with control patients.
Figure 3. Representative images of optical coherence tomography findings in patients presenting with late/very late stent thrombosis. 

A, Uncovered struts, with local accumulations of white thrombus (thr) (see also Figure 3E). B, Interstrut cavities (IC) with small thrombus deposition (thr). C, Severe restenosis with superimposed thrombus (thr). D, Neoatherosclerosis with lipid-rich plaque (L) and plaque rupture (indicated with red arrow). E, Corresponding longitudinal view of the patient with stent thrombosis and uncovered struts shown in Figure 3A. The length of the stented segment is indicated in blue. Thrombus is adherent to uncovered struts along the stented segment, visible as cauliflower-like structures protruding into the lumen (A indicates the location of the cross section in Figure 3A). SB indicates side branch. *Shadow artifact caused by guidewire.
with prior stent implantation. In that study at a median of 615 days after implant, patients with ST had a higher percentage of uncovered (median [interquartile range]) (12.27 [5.50–23.33] versus 4.14 [3.00–6.22], *P* <0.001) and malapposed (4.60 [1.85–7.19] versus 1.81 [0.00–2.99], *P* <0.001) struts. This is also concordant with pathological observations of systematic delayed arterial healing after DES implantation.27 In addition, severe restenosis in the treated segment was relatively frequently observed. This underlines the association between ST and in-stent restenosis as part of the spectrum of stent failure.7,28 The link can be explained by deceleration of flow within the restenotic stented segment, which causes a shift toward a procoagulant state.29 In a minority of late ST cases, additional factors such as residual edge dissection and progression of atherosclerosis with

**Figure 4.** Dominant findings identified by optical coherence tomography imaging according to time interval from index stenting to presentation. A, Acute stent thrombosis (<24 hours). B, Subacute stent thrombosis (24 hours to 30 days). C, Late stent thrombosis (>30 days to 1 year). D, Very late stent thrombosis (>1 year).

**Figure 5.** Dominant findings identified by optical coherence tomography imaging in very late stent thrombosis according to type of stent. BMS indicates bare metal stent; G1-DES, first-generation drug-eluting stent; and G2-DES, second-generation drug-eluting stent.
plaque rupture within the proximal or distal edge segment were considered to be the dominant pathology.

In our study, we found that in-stent neoatherosclerosis, ie, development of de novo atherosclerosis inside the implanted stent, was an important association with ST beyond 1-year cases. Although the diagnosis of neoatherosclerosis can be challenging in the presence of residual overlying thrombus, and its definition remains a matter of some debate, these observations are consistent with findings in late stent failure from autopsy studies, which have documented the presence of neoatherosclerosis in ≈30% of selected autopsy cases and premature and accelerated formation in DES in comparison with uncoated stents.30 One explanation for the more accelerated course in DES is the greater delay in endothelial healing and lack of endothelial integrity within the stented segments of DES in comparison with bare metal stents. It is interesting to note that, in the current study, neoatherosclerosis was frequent in bare metal stents, which is likely explained by the longer duration of follow-up in these patients. Indeed, the majority of patients with a time interval >5 years from stenting had been treated with bare metal stents, and neoatherosclerosis was observed as the dominant finding in the overwhelming majority of cases. In line with this, previous registries showed that the duration of follow-up is the most important risk factor for the occurrence of neoatherosclerosis.30 Effective measures to overcome neoatherosclerosis represent an important unmet need for future clinical investigation. The link between the development of neoatherosclerosis and the progression of native atherosclerotic disease suggests an important role for therapies targeted at secondary prevention of atherosclerosis.31 These observations also highlight the importance of further investigation of alternative approaches to conventional metallic stents in patients who are likely to survive long-term after stent implantation.

The results of our study should be interpreted against the background of recent reports from other investigators. Souteyrand and colleagues32 reported on imaging findings in ST from a cohort of 120 patients who presented with acute coronary syndrome and had OCT performed predominantly in a second sitting according to a deferred intervention model. Similar to our report, they also found that malapposition (34%), stent underexpansion (11%), and neoatherosclerosis (23%) were well-represented underlying mechanisms. In addition, uncovered struts and neoatherosclerosis were frequently observed in patients presenting very late ST. In contrast to our report, malapposition was adjudicated to be a key finding in both early and late ST. Differences in the definition of malapposition as a dominant observation for ST may explain some of the discrepancy with our data set. Taniwaki and colleagues21 also reported on OCT findings in 64 patients with ST, focusing only on those with late or very late thrombosis. In line with our findings, they observed neoatherosclerosis as a major underlying risk factor in a significant proportion of patients (27.6% of cases). The most common finding however, was malapposition, which was the main risk factor in 34.5% of cases beyond 1 year. Uncovered stent struts (12.1%) and stent underexpansion (6.9%) were also identified as additional major causes, which is in agreement with the findings of our study.

Our report has a number of important strengths. First, the analysis represents the largest number of patients presenting with ST and undergoing OCT imaging in the literature to date. In addition, in contradistinction to earlier reports, a high proportion of the thrombosed stents were current-generation DES (≈50%), which are the dominant devices in clinical use at present, and imaging was performed using exclusively contemporary frequency domain OCT. Second, imaging was performed in the acute setting rather than at a deferred time point. Third, data from all participating centers were collected in a prospective manner and recorded in a centralized electronic database. Fourth, analysis of all pullbacks was done in a central core laboratory according to a predefined protocol. In addition, all images were also reviewed by an imaging adjudication panel in dedicated sessions in the core laboratory, with the aim of defining the presence or absence of predetermined characteristics and adjudicating on the dominant cause of the ST based on imaging findings.

Several limitations should be considered when interpreting the results of our report. First, the impact of patient selection must be considered. Only patients presenting to OCT-capable centers were included. Moreover, in patients presenting at OCT-capable centers that did not undergo OCT imaging, the reasons for this were not available for analysis. However, the exclusion of patients presenting with hemodynamic and electric instability was recommended; patients with vessel characteristics unfavorable for image acquisition are also likely unrepresented. Second, the presence of residual thrombus burden in >95% of cases impacts the assessment of the underlying stent and vessel wall findings. In particular, the proportion and extent of stent strut coverage and malapposition may be underestimated. Moreover, offline grayscale signal intensity analysis, a promising approach to characterize neointimal tissue within stents,26 cannot be reliably undertaken. Third, we did not include a control group of patients with prior stent implantation but without ST. This limits our ability to determine the association of observed factors with the clinical presentation of ST, although our findings are concordant with prior case-control studies.26 Fourth, manual thrombectomy was often required to reestablish target vessel patency before imaging. This means that stent/vessel interactions may be altered before image acquisition. Fifth, OCT was not available at the time of index stent implantation. Accordingly, in patients with malapposition at the time of
ST, insight into whether this was present at implantation or acquired during follow-up is not available. Finally, strut fracture was infrequently observed. This may be because of the challenges of OCT imaging when residual thrombus is present, and its impact on 3-dimensional reconstruction analysis, as well.

Conclusions

In patients presenting with ST, a variety of factors are observed on OCT that may contribute to the pathophysiology of this condition. Uncovered and malapposed struts were frequently observed and the prevalence of both decreased with increasing time interval from the index stenting. Moreover, core laboratory–assessed stent underexpansion was present in >40% of cases. The dominant observation, however, varied according to presentation: uncovered struts and underexpansion were most common in acute/subacute ST, and uncovered struts and neoatherosclerosis were most common in late/very late ST. Improved acute deployment techniques with poststent dilatation where appropriate may impact significantly ST by reducing underexpansion and malapposition. In addition, improved management strategies for the prevention and treatment of neoatherosclerosis should be investigated in dedicated studies.

AUTHORS

Tom Adriaenssens, MD, PhD*; Michael Joner, MD*; Thea C. Godschalk, MSc; Nikesh Malik, MD; Fernando Alfonso, MD, PhD; Eron Xhepa, MD; Dries De Cock, MD; Kenichi Komukai, MD; Tomohisa Tada, MD; Javier Cuesta, MD; Vasile Sirbu, MD; Laurent J. Feldman, MD, PhD; Franz-Josef Neumann, MD; Alison H. Goodall, PhD; Ton Heestermans, MD; Ian Buysschaert, MD, PhD; Ota Hlinomaz, MD; Ann Belmans, MSc; Walter Desmet, MD; Jurrien M. ten Berg, MD, PhD; Anthony H. Gershlick, MD; Steffen Massberg, MD; Adnan Kastrati, MD; Giulio Guagliumi, MD; Robert A. Byrne, MB, BCh, PhD; on behalf of the Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators

REFERENCES


SOURCES OF FUNDING

The research leading to these results has received funding from the European Union Seventh Framework Program FP7/2007 to 2013 under grant agreement HEALTH-F2-2010 to 260309 (PRESTIGE). Funding for open access publication is provided by the European Commission.

DISCLOSURES

Dr Adriaenssens is a consultant for St Jude Medical. Dr Joner is a consultant for Biotronik, Orbis Neich, AUM Medical and reports speakers fees from Biotronik, Orbis Neich, Boston Scientific, Abbott Vascular, and Medtronic, and has received research grants from St Jude Medical. Dr Feldman has received research grants from Sanofi and Bristol-Myers Squibb, and is a consultant for St Jude Medical. Dr Goodall reports lecture fees/advisory board fees/travel bursary from Abbott Vascular, AstraZeneca, Boston Scientific, Medicines Company, and Medtronic. Dr Guagliumi is a consultant for Boston Scientific and St Jude Medical and reports research grants from Abbott Vascular, Boston Scientific, and St Jude Medical. Dr Kastrati reports submission of patent applications in relation to drug-eluting stent technology. Dr Byrne reports lectures fees from B. Braun Melsungen, Biotronik, and Boston Scientific and research grants from Boston Scientific and Heartflow.

AFFILIATIONS

From Department of Cardiology, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Belgium (T.A., D.D.C., W.D.); Deutsches Herzzentrum München, Technische Universität München, Germany (M.J., E.X., T.T., A.K., R.A.B.); Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands (T.C.G., J.M.t.B.); Department of Cardiovascular Sciences, University of Leicester & Leicester NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, United Kingdom (N.M., A.H. Goodall, A.H. Gershlick); Hospital Universitario de La Princesa, Madrid, Spain (F.A., J.C.); Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy (K.K., V.S., G.G.); Département de Cardiologie, AP-HP, Hôpital Bichat, Paris, France (L.J.F.); Universitäts-Herzzentrum Freiburg-Bad Krozingen, Germany (F.-J.N.); Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands (T.H.); Antwerp Cardiovascular Institute, ZNA Middelheim, Belgium (I.B.); Department of Cardiology, ICRC, St. Anne University Hospital, Masaryk University, Brno, Czech Republic (O.H.); Department of Biostatistics (I-BioStat), KU Leuven – University of Leuven & Universiteit Hasselt, Belgium (A.B.); Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität, Munich, Germany (S.M.); and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany (S.M., A.K., M.J., R.A.B.).

FOOTNOTES

Received January 12, 2017; accepted May 30, 2017.

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.026788/-/DC1.

Circulation is available at http://circ.ahajournals.org.

DISCLOSURES

Dr Adriaenssens is a consultant for St Jude Medical. Dr Joner is a consultant for Biotronik, Orbis Neich, AUM Medical and reports speakers fees from Biotronik, Orbis Neich, Boston Scientific, Abbott Vascular, and Medtronic, and has received research grants from St Jude Medical. Dr Feldman has received research grants from Sanofi and Bristol-Myers Squibb, and is a consultant for St Jude Medical. Dr Goodall reports lecture fees/advisory board fees/travel bursary from Abbott Vascular, AstraZeneca, Boston Scientific, Medicines Company, and Medtronic. Dr Guagliumi is a consultant for Boston Scientific and St Jude Medical and reports research grants from Abbott Vascular, Boston Scientific, and St Jude Medical. Dr Kastrati reports submission of patent applications in relation to drug-eluting stent technology. Dr Byrne reports lectures fees from B. Braun Melsungen, Biotronik, and Boston Scientific and research grants from Boston Scientific and Heartflow.


Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort)


on behalf of the Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators

Circulation. 2017;136:1007-1021; originally published online July 18, 2017;
doi: 10.1161/CIRCULATIONAHA.117.026788

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/136/11/1007
Free via Open Access

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2017/07/18/CIRCULATIONAHA.117.026788.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

Optical Coherence Tomography Findings in Patients with Coronary Stent Thrombosis

A report of the PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort (PRESTIGE) consortium

*Tom Adriaenssens1, *Michael Joner2, Thea C. Godschalk3, Nikesh Malik4, Fernando Alfonso5, Erion Xhepa2, Dries De Cock1, Kenichi Komukai6, Tomohisa Tada2, Javier Cuesta5, Vasile Sirbu6, Laurent J Feldman7, Franz-Josef Neumann8, Alison H. Goodall4, Ton Heestermans9, Ian Buysschaert10, Ota Hlinomaz11, Ann Belmans12, Walter Desmet1, Jurrien M. ten Berg3, Anthony H. Gershlick4, Steffen Massberg13,14, Adnan Kastrati2,14, †Giulio Guagliumi6, †Robert A. Byrne2, on behalf of the PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort (PRESTIGE) investigators

1Department of Cardiology, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
2Deutsches Herzzentrum München, Technische Universität München, Munich, Germany
3Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
4Department of Cardiovascular Sciences, University of Leicester & Leicester NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK
5Hospital Universitario de La Princesa, Madrid, Spain
6Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
7Département de Cardiologie, AP-HP, DHU FIRE, U-1148 INSERM, Hôpital Bichat, Paris, France
8Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany
9Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
10Antwerp Cardiovascular Institute, ZNA Middelheim, Antwerp, Belgium
11Department of Cardiology, ICRC, St. Anne University Hospital, Masaryk University, Brno, Czech Republic
12Depart of Biostatistics (I-BioStat), KU Leuven – University of Leuven & Universiteit Hasselt, Leuven, Belgium
13Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität, Munich, Germany
14DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
Supplementary methods

OCT quantitative analysis

Metallic stent struts were identified as bright, signal-intense structures with blooming and dorsal shadowing: polymeric bioresorbable stent struts appear as a “black box” area surrounded by bright reflecting frames without abluminal shadowing.1 The first and last analyzed frame at the stented segment was defined as the OCT frame allowing the drawing of a complete circumference using the strut contour, where struts were present in at least 3/4 of the perimeter. Distal and proximal reference measurements were performed in none or minimally diseased cross-sections within 10 mm from the stent edges. For morphometric analysis, standard definitions of cross-sectional area (CSA) and diameter were applied as previously reported.2 Stent and lumen CSA were measured throughout the entire length of the stent. Lumen area was not assessed in presence of remaining thrombus obscuring the luminal border in at least one third of the luminal circumference. Mean reference area was calculated as the sum of the distal and proximal non-stented reference lumen area divided by 2. In case the pullback did not include analyzable distal and proximal non-stented reference segments, the reference area was derived from the proximal and distal most stented segment. Stent expansion index was calculated as minimum stent area divided by mean reference area. Inter-observer variability for core lab morphometric measurements was assessed by repeat analysis of 10 patients performed by a second operator.

Presence of thrombus, stent strut coverage, stent strut apposition, inter-strut cavities, degree and type of neointimal tissue characteristics consistent with neoatherosclerosis were evaluated at frame level. Thrombus was defined as intraluminal protruding mass with irregular borders with or without adherence to stent struts or luminal tissue. The greatest
longitudinal thrombus extent was calculated using the number of consecutive frames with any thrombus. Strut coverage was adjudicated on a frame-level basis. Struts were considered uncovered if any part of the strut was visibly exposed to the lumen. Conversely, struts covered by visible thrombus were classified as thrombus covered struts and counted separately in the analysis. The number of consecutive frames with uncovered struts was counted and the greatest longitudinal extent of uncovered struts was measured.

Malapposition was considered present when the axial distance between the luminal surface of the strut to the lumen contour was greater than the strut thickness (including polymer, if present) including a correction factor to account for strut blooming artifact. Readers blinded to stent type performed the assessment of malapposition. After finishing all measurements, stent type was unblinded and appropriate cut-off values were used to determine coverage and malapposition for each patient. Distance of malapposition was derived from the distance between the luminal surface of the strut and the lumen contour.

Maximum malapposition distance and area of malapposition were recorded. The maximum length of malapposition was derived by the number of consecutive frames with malapposed struts. Inter-strut cavities (or coronary in-stent evaginations) were defined as the presence of an outward bulge in the luminal vessel contour between apposed struts with a maximum depth of the bulge greater than 1/3 of the lumen diameter. Atherosclerotic changes of the neointima (neoatherosclerosis) were defined by the presence of one or more of the following: lipid laden tissue within the stent, defined as a signal-poor region with diffuse border and light signal attenuation, possibly masking deep strut detection; thin-cap fibroatheroma (TCFA), defined as plaque with lipid-laden tissue with a fibrous cap thickness ≤ 65 μm at the thinnest measured point, or neointimal calcification, characterized by a signal-poor region with sharp demarcation within the overlying neointima. In the core lab
analysis, neoatherosclerosis was adjudicated when lipid-laden tissue or TCFA involved more than 50% of the analyzable arc at the involved cross-section.

**Supplementary results**

*Comparison of patients with and without OCT imaging*

In a sensitivity analysis comparing patients with ST with analyzable OCT imaging who were included in the present analysis (n=217) versus those without analyzable OCT imaging (n=458) we found was no significant difference in the proportion of patients with acute/subacute or late/very late ST 62/217 (28.6%) versus 150/455 (33.0%) and 155/217 (71.4%) versus 305/455 (67.0%) respectively; P=0.25).

Baseline characteristics of patients with and without OCT imaging are shown in **Supplementary Table 2**.

*OCT core laboratory analysis*

Mean difference between methods and within-patient standard deviation for proximal lumen area, distal lumen area and minimal stent area were 1.03 and 1.43 mm$^2$, 0.02 and 0.20 mm$^2$, -0.24 and 0.27 mm$^2$, respectively. For these parameters, repeatability coefficients and intra-class correlation coefficients (Shrout and Fleiss) were 3.96 and 0.62, 0.57 and 0.99, 0.76 and 0.97 respectively.
<table>
<thead>
<tr>
<th></th>
<th>Early stent thrombosis</th>
<th>Late/very late stent thrombosis</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Platelet reactivity with VerifyNow P2Y₁₂ (n=49)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High platelet reactivity</td>
<td>15/17 (88.2%)</td>
<td>22/32 (68.8%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Platelet reactivity units</td>
<td>257±86</td>
<td>245±86</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Platelet reactivity with Multiplate adenosine diphosphate (ADP) (n=51)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High platelet reactivity</td>
<td>15/20 (75.0%)</td>
<td>19/31 (61.3%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Platelet reactivity units (U)</td>
<td>76±46</td>
<td>63±33</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Data are shown as n (%) or mean ± standard deviation
Supplementary Table 2. Baseline characteristics of patients presenting with stent thrombosis with and without analyzable OCT imaging

<table>
<thead>
<tr>
<th></th>
<th>With OCT imaging (N= 217)</th>
<th>Without OCT imaging (N= 458)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.7±11.9</td>
<td>64.1±11.8</td>
<td>0.69</td>
</tr>
<tr>
<td>Male</td>
<td>178/217 (82.0%)</td>
<td>374/458 (81.7%)</td>
<td>0.91</td>
</tr>
<tr>
<td>Diabetes insulin dependent</td>
<td>54/217 (24.9%)</td>
<td>105/455 (19.4%)</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>8/214 (12.9%)</td>
<td>41/435 (9.4%)</td>
<td>0.15</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>181/193 (93.8%)</td>
<td>376/420 (89.5%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>99/211 (46.9%)</td>
<td>229/451 (50.8%)</td>
<td>0.36</td>
</tr>
<tr>
<td>Active smoker</td>
<td>62/210 (29.5%)</td>
<td>123/448 (27.5%)</td>
<td>0.58</td>
</tr>
<tr>
<td>Severely impaired left ventricular function*</td>
<td>9/217 (4.2%)</td>
<td>15/451 (3.3%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Prior bypass operation</td>
<td>14/217 (6.5%)</td>
<td>35/455 (7.7%)</td>
<td>0.56</td>
</tr>
<tr>
<td>Prior myocardial infarction</td>
<td>100/217 (46.1%)</td>
<td>303/427 (71.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>9/217 (4.2%)</td>
<td>19/453 (4.2%)</td>
<td>0.98</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>ST-elevation myocardial infarction</td>
<td>158/217 (72.8%)</td>
<td>361/458 (78.8%)</td>
<td></td>
</tr>
<tr>
<td>Non-ST-elevation myocardial infarction</td>
<td>46/217 (21.2%)</td>
<td>79/458 (17.3%)</td>
<td></td>
</tr>
<tr>
<td>Unstable angina</td>
<td>10/217 (4.6%)</td>
<td>12/458 (2.6%)</td>
<td></td>
</tr>
<tr>
<td>Culprit vessel</td>
<td></td>
<td></td>
<td>0.53</td>
</tr>
<tr>
<td>Left main only</td>
<td>2/214 (0.9%)</td>
<td>9/456 (2.0%)</td>
<td></td>
</tr>
<tr>
<td>LAD only</td>
<td>90/214 (42.1%)</td>
<td>177/456 (38.8%)</td>
<td>0.42</td>
</tr>
<tr>
<td>LCx only</td>
<td>29/214 (13.5%)</td>
<td>56/456 (12.3%)</td>
<td>0.64</td>
</tr>
<tr>
<td>RCA only</td>
<td>78/214 (36.5%)</td>
<td>182/456 (39.9%)</td>
<td>0.39</td>
</tr>
<tr>
<td>......LAD and LCx</td>
<td>6/214 (2.8%)</td>
<td>3/456 (0.7%)</td>
<td>0.07</td>
</tr>
<tr>
<td>......LAD and RCA</td>
<td>2/214 (0.9%)</td>
<td>2/456 (0.4%)</td>
<td>0.77</td>
</tr>
<tr>
<td>......LCx and RCA</td>
<td>3/214 (1.4%)</td>
<td>1/456 (0.2%)</td>
<td>0.20</td>
</tr>
<tr>
<td>Saphenous vein graft</td>
<td>4/214 (1.9%)</td>
<td>26/456 (5.7%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Bifurcation lesion</td>
<td>38/205 (18.5%)</td>
<td>76/438 (17.4%)</td>
<td>0.71</td>
</tr>
<tr>
<td>Number of stents implanted in vessel with stent thrombosis</td>
<td>333</td>
<td>685</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>-----</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td><strong>Stent type at index procedure</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- bare metal stent</td>
<td>110/333 (33.0%)</td>
<td>187/685 (27.3%)</td>
<td></td>
</tr>
<tr>
<td>- early generation DES</td>
<td>45/333 (1.0%)</td>
<td>120/685 (17.5%)</td>
<td></td>
</tr>
<tr>
<td>- newer generation DES</td>
<td>163/333 (48.9%)</td>
<td>316/685 (46.1%)</td>
<td></td>
</tr>
<tr>
<td>- bioresorbable DES</td>
<td>6/333 (1.8%)</td>
<td>11/685 (1.6%)</td>
<td></td>
</tr>
<tr>
<td>- unknown</td>
<td>9/333 (2.7%)</td>
<td>51/685 (7.4%)</td>
<td></td>
</tr>
<tr>
<td><strong>Stent diameter (mm)</strong></td>
<td>3.2±1.4</td>
<td>3.1±0.5</td>
<td></td>
</tr>
<tr>
<td><strong>Stent length (mm)</strong></td>
<td>19.8±6.3</td>
<td>20.6±7.7</td>
<td></td>
</tr>
<tr>
<td><strong>TIMI flow at presentation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0/1</td>
<td>168/212 (79.3%)</td>
<td>370/451 (82.0%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>21/212 (9.9%)</td>
<td>33/451 (12.6%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>23/212 (13.1%)</td>
<td>48/451 (9.9%)</td>
<td></td>
</tr>
</tbody>
</table>

Data are shown as n (%) or mean ± standard deviation

*severely impaired left ventricular function was defined as ejection fraction <30%
**Supplementary Table 3: Estimated probabilities for findings according to time interval between index stenting and stent thrombosis at a frame-level adjusted by generalized linear mixed models**

<table>
<thead>
<tr>
<th>Predicted average probability* (95% CI) for a frame to have any*</th>
<th>Acute stent thrombosis</th>
<th>Subacute stent thrombosis</th>
<th>Late stent thrombosis</th>
<th>Very late stent thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncovered Struts</td>
<td>77.4% (56.4%; 90.0%)</td>
<td>57.0% (43.2%; 69.8%)</td>
<td>22.4% (11.1%; 39.9%)</td>
<td>5.3% (3.6%; 7.6%)</td>
</tr>
<tr>
<td>Thrombus Covered Struts</td>
<td>17.3% (7.3%; 35.6%)</td>
<td>24.5% (15.7%; 36.1%)</td>
<td>3.8% (1.5%; 9.3%)</td>
<td>3.2% (2.1%; 4.9%)</td>
</tr>
<tr>
<td>Uncovered or Thrombus-Covered Struts</td>
<td>99.3% (96.1%; 99.9%)</td>
<td>96.6% (92.4%; 98.5%)</td>
<td>34.3% (15.0%; 60.7%)</td>
<td>9.6% (6.2%; 14.5%)</td>
</tr>
<tr>
<td>Malapposed Struts</td>
<td>21.8% (8.4%; 45.6%)</td>
<td>8.5% (4.6%; 15.3%)</td>
<td>6.7% (2.5%; 16.3%)</td>
<td>2.0% (1.2%; 3.3%)</td>
</tr>
<tr>
<td>Struts with Neoatherosclerosis</td>
<td>0.0% (0.0%; 0.0%)</td>
<td>0.0% (0.0%; 0.0%)</td>
<td>0.0% (0.0%; 0.0%)</td>
<td>2.8% (1.3%; 5.9%)</td>
</tr>
<tr>
<td>Interstrut Cavities</td>
<td>0.0% (0.0%; 0.0%)</td>
<td>0.1% (0.0%; 0.3%)</td>
<td>1.2% (0.3%; 4.5%)</td>
<td>0.7% (0.3%; 1.4%)</td>
</tr>
</tbody>
</table>

Estimates were obtained using a mixed effects logistic regression model, including a fixed effect for time and a random intercept per patient

* Predicted probability for an 'average' patient, i.e. with random intercept of zero
Supplementary Table 4: Results of imaging adjudication committee analysis for contributory findings in stent thrombosis

<table>
<thead>
<tr>
<th>Findings</th>
<th>Acute stent thrombosis (N=15)</th>
<th>Subacute stent thrombosis (N=47)</th>
<th>Late stent thrombosis (N=21)</th>
<th>Very late stent thrombosis (N=134)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncovered struts</td>
<td>15 (100%)</td>
<td>43 (91.5%)</td>
<td>13 (61.9%)</td>
<td>65/134 (48.5%)</td>
</tr>
<tr>
<td>Malapposed struts</td>
<td>9 (60%)</td>
<td>24 (51.1%)</td>
<td>8 (38.1%)</td>
<td>37/134 (27.6%)</td>
</tr>
<tr>
<td>Underexpansion</td>
<td>3 (20%)</td>
<td>31 (66.0%)</td>
<td>8 (38.1%)</td>
<td>35/134 (26.1%)</td>
</tr>
<tr>
<td>Severe restenosis</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>8 (38.1%)</td>
<td>43/134 (32.1%)</td>
</tr>
<tr>
<td>Neoatherosclerosis</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>52/134 (38.8%)</td>
</tr>
<tr>
<td>Neoatherosclerosis with rupture</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>31/134 (23.1%)</td>
</tr>
<tr>
<td>Inter strut cavities</td>
<td>0 (0%)</td>
<td>1 (2.1%)</td>
<td>5 (23.8%)</td>
<td>18/134 (13.4%)</td>
</tr>
<tr>
<td>Distal edge dissection</td>
<td>1 (6.7%)</td>
<td>3 (6.4%)</td>
<td>0 (0%)</td>
<td>1/134 (0.8%)</td>
</tr>
<tr>
<td>Proximal edge dissection</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1/134 (0.8%)</td>
</tr>
<tr>
<td>Edge segment disease &amp; plaque rupture</td>
<td>2 (13.3%)</td>
<td>5 (10.6%)</td>
<td>4 (19.1%)</td>
<td>16/134 (11.9%)</td>
</tr>
<tr>
<td>Stent overlap</td>
<td>3 (20.0%)</td>
<td>13 (27.7%)</td>
<td>5 (23.8%)</td>
<td>33/134 (24.6%)</td>
</tr>
<tr>
<td>Stent fracture</td>
<td>0 (0%)</td>
<td>1 (2.1%)</td>
<td>0 (0%)</td>
<td>1/134 (0.8%)</td>
</tr>
</tbody>
</table>
Supplementary Figure 1. Outline of work flow of core lab analysis

- Observers blinded to stent type and clinical presentation
- Quality screening: 14/231 not sufficient quality
- Morphometric Analysis
- Frame/strut level qualitative/quantitative analysis

Distal Proximal
Stent segment = Target site
Proximal Reference Segment
Distal Reference segment
Analysis start Analysis end

Stent End Stent End

Most normal looking frame

1 mm

Observers blinded to stent type and clinical presentation

Most normal looking frame

Distal Reference segment

Analysis start

10.0 mm

Proximal Reference Segment

Analysis end

10.0 mm

Stent segment = Target site
Supplementary Figure 2. Study flow chart

675 patients presenting with stent thrombosis

231 patients undergoing OCT image acquisition

217 patients analysed in OCT core lab

444 patients not presenting at OCT center or not undergoing OCT imaging

14 patients excluded from further analysis
- blood contamination [n=6]
- excessive remaining thrombus [n=8]

OCT = optical coherence tomography
References


Appendix A: General description of the PRESTIGE Consortium

In 2010, a consortium of 14 European institutions joined forces to investigate stent thrombosis. The project consortium was named PRESTIGE—PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort—and was coordinated by the Deutsches Herzcentrum München in Munich, Germany. It has run for 4 years, 2010–14. The project was funded by the European Commission under the Seventh Framework Programme (Grant Agreement No.: HEALTH-F2-2010-260309). Within the project, the scientists want to develop new concepts to identify and prevent ST. The strategy includes a basic scientific approach to decrypt the molecular and cellular mechanisms underlying ST, a bio-engineering approach focused on the development and testing of new intravascular imaging tools and stent materials to prevent stent thrombosis, plus a clinically-orientated effort to better characterize the burden of ST across Europe.

The consortium is led by Prof. Adnan Kastrati and Prof. Steffen Massberg and has participants from nine European Union countries, involving both academic centres and small- and medium-sized companies.

PRESTIGE Consortium

Partners: Deutsches Herzzentrum München (DHM); Azienda Ospedaliera Papa Giovanni XXIII (BER); Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie (KRAK); St. Antonius Ziekenhuis Nieuwegein (NIE); University of Leicester (ULEIC); Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH (UHZ); Institut national de la santé et de la recherche médicale (INSERM); Rigas Tehniska Universitate (RTU); Kitozyme S.A. (KIZ); Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (HMGU); Katholieke Universiteit Leuven (K.U.LEUVEN); Servicio Madrileño de Salud: Hospital Universitario Clinico San Carlos (SC) and Hospital Universitario de La Princesa (HULP); BIOTRONIK SE & Co. KG (BIO); neoplas GmbH (NEO).
Investigators: **Belgium**: Tom Adriaenssens (K.U.LEUVEN), Emanuele Barbato, (Cardiovascular Center, Aalst), Ian Buysschaert (ZNA Middelheim), Mickaël Chausson (initially KIZ, now Synolyne Pharma), Dries De Cock (K.U.LEUVEN), Jo Dens (Oost-Limburg Hospital, Genk), Walter Desmet (K.U.Leuven), Sandrine Gautier (initially KIZ, now Synolyne Pharma), Paul Vermeersch (ZNA Middelheim), Peter Sinnaeve (K.U.LEUVEN); **Czech Republic**: Ota Hlinomaz (ICRC, St. Anne University Hospital, Brno), Ladislav Groch (ICRC, St. Anne University Hospital, Brno), Jan Sitar (ICRC, St. Anne University Hospital, Brno), Michal Rezek (ICRC, St. Anne University Hospital, Brno), Jiri Semenka (ICRC, St. Anne University Hospital, Brno), Martin Novak (ICRC, St. Anne University Hospital, Brno), Jiri Sikora (ICRC, St. Anne University Hospital, Brno); **France**: Helene Abergel (INSERM), Jeremie Abtan (INSERM), Pierre Aubry (INSERM), Gregory Ducrocq (INSERM), Laurent Feldman (INSERM), Eric Garbarz (INSERM), Dominique Himbert (INSERM), Martine Jandrot-Perrus (INSERM), Jean-Michel Juliard (INSERM), Didier Letourneur (INSERM), Pierre Mangin (INSERM), Mohammed Nejjari (INSERM), Véronique Olivier (INSERM), Caroline Roques (INSERM), Emmanuel Sorbets (INSERM), Ph. Gabriel Steg (INSERM), Marina Urena-Alcazar (INSERM); **Germany**: Robert A. Byrne (DHM), Sue Chandraratne (initially DHM, later Klinikum der Universität München), Matthias Gratz (BIO); Michael Joner (DHM), Adnan Kastrati (DHM), Elisabeth Kennerknecht (DHM), Ildiko Konrad (DHM), Tobias Kopp (DHM), Steffen Massberg (initially DHM, later Klinikum der Universität München), Franz-Josef Neumann (UHZ), Vasilis Ntziachristos (HMGU), Sheryl Opinaldo (initially DHM, later Klinikum der Universität München), Vanessa Philippi (initially DHM, later Klinikum der Universität München), Julia Riegger (initially DHM, later Klinikum der Universität München), Amir Rosenthal (HMGU), Alexander Rzany (BIO), Christian Schulz (initially DHM, later Klinikum der Universität München), Kristin Steigerwald (DHM), Tomohiso Tada (DHM), Anna Titova (initially DHM, later Klinikum der Universität München), Dietmar Trenk (UHZ), Christian Valina (UHZ), Andreas Vogelsang (NEO), Erion Xhepa (DHM); **Italy**: Chiara Bernelli (BER); Micol Coccato (BER), Giulio Guagliumi (BER), Kenichi
Komukai (BER), Vasile Sirbu (BER); Latvia: Garry Kerch (RTU); The Netherlands: Giovanni Amoroso (Onze Lieve Vrouwe Gasthuis, Amsterdam), Jurriën ten Berg (NIE), Willem J.M. Dewilde (Amphia Ziekenhuis, Breda), Thea C. Godschalk (NIE), Antonius A.C.M. Heestermans (Noordwest Ziekenhuisgroep, Alkmaar), Darshni A. Jhagroe (NIE), Joanne J. Wykrzykowska (Academisch Medisch Centrum, Amsterdam), Mark H.M. Winkens (TweeSteden ziekenhuis, Tilburg); Poland: Dariusz Dudek (KRAK), Łukasz Rzeszutko (KRAK), Roman Wojdyla (KRAK), Wojciech Zasada (KRAK); Spain: Fernando Alfonso (HULP, SC), Javier Cuesta (HULP), Miguel Medina (SC); United Kingdom: Colin Berry (University of Glasgow; Golden Jubilee National Hospital, Glasgow), James Cotton (The Royal Wolverhampton Hospitals NHS Trust), Nick Curzen (University Hospital Southampton NHS Foundation Trust), Margaret McEntegart (Golden Jubilee National Hospital, Glasgow), Robert Gerber (East Sussex Healthcare NHS Trust), Anthony Gershlick (ULEIC), Alison H. Goodall (ULEIC), Simon Hetherington (Kettering General Hospital NHS Foundation Trust), Jonathan Hill (King's College Hospital NHS Foundation Trust), Damian Kelly (Derby Hospitals NHS Foundation Trust), Nikesh Malik (ULEIC), Keith Oldroyd (Golden Jubilee National Hospital, Glasgow), Helen Routledge (Worcestershire Acute Hospitals NHS Trust), Joanne Shannon (Frimley Health Foundation Trust), Venkatesan Suresh (Plymouth Hospitals NHS Trust), Azfar Zahman (Newcastle Upon Tyne Hospitals NHS Foundation Trust).

Work Packages:

Work package 1 (WP1): Gaining a better mechanistic understanding of the molecular and cellular events triggering late ST

Leader: Martine Jandrot-Perrus (INSERM), Co-Leader: Steffen Massberg (initially DHM, later Klinikum der Universität München)

Work package 2 (WP2): Developing and validating novel strategies to reduce late ST
Leader: Michael Joner (DHM), Co-Leader: Didier Letourneur (INSERM)

Work package 3 (WP3): Developing and evaluating novel imaging technologies
Leader: Giulio Guagliumi (BER), Co-Leader: Vasilis Ntziachristos (HMGU)

Work package 4 (WP4): Performing a multi-stranded characterisation of patients with late ST
Leader: Walter Desmet (K.U.LEUVEN), Co-Leader: Anthony Gershlick (ULEIC)

OCT imaging adjudication committee: This group was comprised of experts with documented expertise in clinical and preclinical OCT use and evaluation of coronary stents.
Members: Tom Adriaenssens (K.U.LEUVEN), Takashi Akasaka (Wakayama University, Japan), Fernando Alfonso (SC), Robert A. Byrne (DHM), Giulio Guagliumi (BER), Michael Joner (DHM), Vasile Sirbu (BER).

OCT core lab: Tom Adriaenssens (K.U.LEUVEN), Robert A. Byrne (DHM), Dries De Cock (K.U.LEUVEN), Thea Godschalk (NIE), Kenichi Komukai (BER), Nikesh Malik (ULEIC), Tomohisa Tada (DHM); Erion Xhepa (DHM)

Thrombus analysis core lab: Sue Chandraratne, Steffen Massberg, Sheryl Opinaldo, Vanessa Philippi, Julia Riegger, Christian Schulz, Anna Titova (all initially DHM, later Klinikum der Universität München).